PHP
IMNM icon

Parkman Healthcare Partners’s Immunome IMNM Stock Holding History

Parkman Healthcare Partners’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.82M Buy
403,487
+125,675
+45% +$2.8M 0.91% 42
2025
Q4 		$5.97M Sell
277,812
-73,319
-21% -$1.29M 0.57% 55
2025
Q3 		$4.11M Buy
+351,131
New +$3.49M 0.43% 67

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Parkman Healthcare Partners's IMNM Position: Q1 2026 in Review

Parkman Healthcare Partners increased its Immunome (IMNM) stake by 45% in Q1 2026, buying an estimated $2.8M and bringing the position to 403,487 shares worth $8.82M. The position accounts for 0.91% of the portfolio, ranked #42.

Parkman Healthcare Partners first reported a position in IMNM in Q3 2025 and has held it in 3 quarters since. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • Parkman Healthcare Partners held 403,487 shares of Immunome worth $8.82M as of Q1 2026.
  • Parkman Healthcare Partners bought 125,675 Immunome shares in Q1 2026, an estimated $2.8M.
  • Immunome made up 0.91% of Parkman Healthcare Partners's portfolio in Q1 2026, its #42 holding.
  • Parkman Healthcare Partners first reported a position in Immunome in Q3 2025 and has held it in 3 quarters since.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on Parkman Healthcare Partners's 13F filing for Q1 2026, filed 15 May 2026.